Biomaterials (Elsevier) Submission Guide: Portal, Material-Plus-Biology Bar & Routing

Source: Biomaterials on ScienceDirect, Clarivate JCR 2024, SciRev community data, accessed May 2026.

Biomaterials does not publish a hard word cap. The convention reconstructed from same-publisher sister journal Acta Biomaterialia is the operational guide:

• Research article: typical 6000 to 8000 words main text, 6 to 8 main figures

• Review article: comprehensive treatment, typical 10000 to 12000 words

• Short Communication: typical 3000 to 4000 words, 4 figures

Manuscripts exceeding ~10 printed pages typically get returned for shortening (Elsevier biomaterials-family convention; sister Acta Biomaterialia explicitly caps at ~10 printed pages and ~8 figures with more than 25 typescript pages returned for shortening). Highlights mandatory (3 to 5 bullets, 85 characters or fewer). Graphical abstract mandatory.

Source: Biomaterials Guide for Authors.

Biomaterials' 5-to-8-month end-to-end timeline reflects the substantive material-plus-biology peer review and the journal's near-zero accept-on-first-review rate.

Day 0 to 2: Technical check

Submission lands in Editorial Manager. Automated checks run on Highlights formatting, graphical abstract specs, declaration completeness, CRediT statement, and file types.

Day 3 to 20: Editorial triage (desk-decision window)

The handling editor reads the cover letter, Highlights, graphical abstract, and abstract for the material-plus-biology bar. Desk rejects arrive across this window for pure-materials without bio-interface, pure-biology without materials-design contribution, or scope drift to sister venues.

Week 3 to 12: Peer review

Typically 2 to 3 reviewers per manuscript. The biomaterials reviewer pool overlaps with Acta Biomaterialia, Advanced Healthcare Materials, and Biomaterials Science. SciRev reports 2.8 reports per submission average.

Week 8 to 14: First decision

Decision arrives across this window. Major revision is most common; minor revision for stronger submissions. Accept-on-first-review is rare in the SciRev community reports.

Week 12 to 22: Revision round

Major revisions get 4 to 8 weeks of author time plus a second review cycle. Average is 1.5 revision rounds per SciRev community data. Total end-to-end timeline for accepted manuscripts is 5 to 8 months.

Source: SciRev community data for Biomaterials, accessed May 2026.

The single most consequential decision before submission is which biomaterials venue to target. The material-plus-biology bar is load-bearing; sister venues handle either-direction work.

The routing rule: material-design plus biological mechanism with in vivo validation goes to Biomaterials; broader biomaterials with device or surface emphasis goes to Acta Biomaterialia; chemistry-protagonist biomaterials goes to Biomaterials Science (RSC); engineering-protagonist biomaterials goes to ACS Biomaterials Science & Engineering; translational healthcare-emphasis biomaterials goes to Advanced Healthcare Materials.

Biomaterials editors screen on three operational signals beyond the technical-check gates:

1. Material design plus biological mechanism or validated function. Both halves required. The cover letter must name both the material-design contribution and the biological mechanism or validated function. Single-half submissions route to sister venues.

1. In vivo validation for translational claims. Manuscripts making translational claims about clinical or in-body performance need in vivo validation; in vitro alone rarely clears the bar. Pre-clinical animal models, ex vivo tissue, or human-derived primary cells provide stronger validation than cell-line assays alone.

1. Meaningful comparator or baseline material. Manuscripts that present a new biomaterial without comparing against a state-of-the-art baseline material routinely fail the contribution-test. The fix is to include head-to-head comparison with an established benchmark material.

Recent issues span scaffolds for tissue engineering with mechanistic validation, drug delivery systems with in vivo biodistribution, implant materials with osseointegration mechanism, biointerfaces with cell-material interaction analysis, nanomaterials with biological mechanism, hydrogels with mechanical-biological coupling, immunomodulatory biomaterials, regenerative medicine with stem-cell-material integration, and emerging methodologies including machine-learning-assisted biomaterial design.

For specific recent papers, see Biomaterials on ScienceDirect.

This guide tells you what Biomaterials editors look for before reviewer assignment, and Manusights checks whether your paper passes the material-design, biological-mechanism, validation, comparator-table, Highlights, graphical-abstract, methods, controls, and cover-letter tests that official Elsevier guidance cannot evaluate from a generic checklist. Paid Manusights reviews are covered by a 60-day money-back guarantee, and we never train on submitted manuscripts.

Across biomaterials manuscripts targeting Biomaterials, three desk-screen patterns recur because the journal is neither a pure materials-chemistry venue nor a biology journal with materials in the methods. (Per Elsevier published guidance, Biomaterials is the flagship title in Elsevier's biomaterials science portfolio, requires the standard Elsevier artifact package, uses Highlights and graphical abstract assets, and sits beside Materials Today Bio, Biomaterials Advances, Biomaterials and Biosystems, and Acta Biomaterialia.)

These patterns are testable in the abstract, cover letter, Highlights, graphical abstract, figures, methods, comparator table, ethics statement, supplementary material, references, and cross-publisher redirect plan before Editorial Manager upload.

Material design is strong but the biological mechanism is decorative

Across Biomaterials-targeted manuscripts, the most frequent failure is a materials paper with a late biological assay attached. The synthesis is often credible: a new hydrogel, nanoparticle, scaffold, implant coating, bioactive glass, polymer network, extracellular-matrix mimic, drug-delivery carrier, or surface-functionalized construct.

The figures show SEM, TEM, XRD, FTIR, XPS, rheology, degradation, mechanical testing, release kinetics, or porosity, and the abstract claims biomedical relevance. The manuscript components that fail are the biological mechanism paragraph, comparator table, controls, dose-response design, methods, figure order, and supplementary material. Biomaterials editors need the material design to explain a biological outcome, not merely sit beside one. Cell viability alone rarely proves mechanism.

A scaffold paper needs cell-material interaction, differentiation, immune response, vascularization, or tissue-integration evidence proportional to its claim. A drug-delivery paper needs release behavior tied to pharmacology, uptake, biodistribution, toxicity, or disease-model response. An implant paper needs surface-property changes tied to osseointegration, inflammation, bacterial adhesion, wear, corrosion, or host response.

If the manuscript's strongest sentence is "we synthesized a novel material and confirmed biocompatibility," Chemistry of Materials, ACS Applied Materials & Interfaces, Materials Horizons, Journal of Materials Chemistry B, or Materials Today Chemistry may be cleaner.

The fix is to move the biological mechanism into Figure 1 or Figure 2, name the comparator material, add mechanism-matched controls, and make the cover letter state the material-design move and biological consequence in the same sentence.

Check whether your Biomaterials manuscript connects material design to biology →

Biology story is strong but the material is not a contribution

In Manusights reviews, the second recurring pattern is the mirror-image failure: the paper answers a real biological or translational question but uses a familiar material platform without enough design novelty. The biological data may be substantial: organoid response, immune modulation, wound healing, bone regeneration, tumor microenvironment behavior, infection control, neural repair, stem-cell differentiation, or drug-delivery efficacy.

The problem is that the material operates as a carrier, scaffold, coating, or convenience method rather than a biomaterials advance. The failing manuscript components are usually the introduction, material-characterization figure, methods details, structure-property paragraph, controls, references, and cover letter. Biomaterials expects material design and biological function to travel together.

If the biological finding would remain essentially unchanged with a standard hydrogel, PLGA particle, collagen scaffold, titanium coating, chitosan matrix, PEG network, or liposome, the editor may see a biology paper using materials rather than a Biomaterials paper.

Redirect targets include Acta Biomaterialia for materials-focused biomaterials, Biomaterials Advances for broader biomedical applications, Materials Today Bio for general biomaterials, Advanced Healthcare Materials for translational healthcare-materials emphasis, Tissue Engineering Part A, Journal of Controlled Release, ACS Applied Bio Materials, and specialty cell-biology or regenerative-medicine journals.

The fix is to prove that the material architecture creates the biological result: tune stiffness, porosity, ligand density, degradation, charge, morphology, release profile, or surface chemistry and show that the biological outcome follows the material variable rather than the payload or cell model alone.

Check whether your Biomaterials manuscript makes the material itself a contribution →

Translational claim outruns validation, comparator, or artifact readiness

For Biomaterials submissions, the third pattern is a manuscript whose biomedical claim is larger than its evidence package.

The abstract and cover letter promise clinical translation, in vivo performance, implant readiness, therapeutic superiority, infection control, tissue regeneration, targeted delivery, or patient-relevant function, but the figures stop at in vitro cytotoxicity, one cell line, short-term release, a single animal endpoint, or no state-of-the-art comparator. Biomaterials editors and reviewers read the validation package as the credibility test.

The failing components are the animal or human-subject ethics statement, methods, statistics, controls, comparator material, disease model, biodistribution or degradation data, supplementary raw data, graphical abstract, and Highlights.

Translational language needs validation proportional to the claim: in vivo or ex vivo evidence where the claim is in-body, primary cells or organoids where the cell-line model is too weak, realistic dosing and release windows, head-to-head comparison with the current material standard, and adverse-response or safety readouts where the application demands them.

If the evidence is early-stage but useful, Acta Biomaterialia, Biomaterials Science, ACS Biomaterials Science & Engineering, Advanced Healthcare Materials, Journal of Biomedical Materials Research Part A, Journal of Controlled Release, or Bioactive Materials may be more credible. The fix is not always to add an animal study.

Sometimes the better move is to narrow the claim, reposition as mechanism or platform work, move speculative clinical language out of the abstract, and make the cover letter align the evidence actually present with the Biomaterials bar.

Check whether your Biomaterials validation package matches the claim →

Check whether your Biomaterials manuscript is submission-ready →

• Biomaterials overview

• Is Biomaterials a good journal?

• Biomaterials review time

• Biomaterials Under Review status guide

• Acta Biomaterialia Submission Guide

• Biomaterials Science Submission Guide

• ACS Biomaterials Science and Engineering Submission Guide